Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07540832Phase 1Not Yet Recruiting

Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC

Role: lead

NCT07494435Phase 2Not Yet Recruiting

Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC

Role: lead

NCT06309485Phase 2Recruiting

Phase 2 Study of WGI-0301 for Advanced HCC

Role: lead

NCT05267899Phase 1Unknown

A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors

Role: lead

All 4 trials loaded